Comparative Pharmacology
Head-to-head clinical analysis: PARLODEL versus PRAMIPEXOLE DIHYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PARLODEL versus PRAMIPEXOLE DIHYDROCHLORIDE.
PARLODEL vs PRAMIPEXOLE DIHYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dopamine D2 receptor agonist; inhibits prolactin secretion by binding to pituitary and hypothalamic D2 receptors.
Non-ergoline dopamine agonist that selectively binds to D2 and D3 dopamine receptors, particularly D3, in the striatum and substantia nigra, mimicking dopamine's effects to improve motor function in Parkinson's disease.
Parkinson disease: initial 1.25 mg orally twice daily, increase by 2.5 mg/day every 2-4 weeks; usual range 15-30 mg/day. Hyperprolactinemia: initial 1.25-2.5 mg orally once daily, titrate to 2.5 mg twice daily; maintenance 2.5-15 mg/day.
0.125 mg orally three times daily, titrated as tolerated to maximum 4.5 mg/day
None Documented
None Documented
Terminal elimination half-life: 12-14 hours (biphasic, initial half-life 6-8 hours); clinical context: steady-state achieved in 2-3 days.
Terminal half-life: 8–12 hours in young adults; up to 15–18 hours in elderly. Clinical context: Once-daily dosing; steady-state in 2–4 days.
Renal: approximately 60% as metabolites, 6% as unchanged drug; biliary/fecal: approximately 40% as metabolites and unchanged drug.
Renal: ~90% unchanged in urine; biliary/fecal: ~2%.
Category C
Category A/B
Dopamine Agonist
Dopamine Agonist